Amarin Corp Plc (AMRN)

[north40000]

I am thinking that Amarin may have known of DES condition of patients as they entered the R-I trial years ago. It may have learned during the trial, that a certain subset of, or all, patients lost their respective DES conditions as the trial proceeded---Amarin may have even asked new entrants in the trial, in subsequent years, whether they possessed a DES condition before they entered the trial. Certainly extant literature caused, or should have caused, such a question be asked and documented, in light of knowledge evinced by that literature that DES was essentially cured by the anti-inflammatory properties of the omega-3 fatty acid EPA.

Following the interim look by IDMC a while back, I understand an unknown number of other indications or sought results[termed secondary] were added to the clinical trial protocol---someone here estimated 30 or so.

One of the 30 could be measurement of DES in all patients from start or interim to unblinding of trial, resulting from the administration of V vs administration of placebo. In my wildest imagination, the clinical trial you ask for may already be proceeding. And I bet the FDA will not ask for a 2nd confirmatory trial to be conducted.